SCHEMBL27240208

SCHEMBL27240208

COc1nc(Br)cc(C(N)=O)c1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.44
NNMT P40261 4/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 2/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
EDNRA P25101 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36
TSHR P16473 1/20 0.35
APOBEC3A P31941 1/20 0.35
HTT P42858 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
LMNA P02545 1/20 0.35
SIRT6 Q8N6T7 1/20 0.34
CDC7 O00311 1/20 0.34
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26639806 0.87 POLB (0.47) POLBKDM4EALDH1A1GLAHPGD
SCHEMBL428407 0.76 NNMT (0.53) POLBNNMTKDM4EALDH1A1GLA
SCHEMBL22684175 0.74 POLB (0.38) POLBALDH1A1
SCHEMBL30432264 0.74 POLB (0.38) POLBALDH1A1
SCHEMBL27403573 0.74 KDM4E (0.40) POLBNNMTKDM4EALDH1A1GLA
SCHEMBL31364688 0.74 CASP1 (0.41) POLBNNMTALDH1A1LMNA
SCHEMBL25300381 0.73 KDM4E (0.53) POLBNNMTKDM4EALDH1A1GLA
SCHEMBL25205338 0.73 POLB (0.39) POLBKDM4EALDH1A1GAAHPGD
SCHEMBL18337885 0.72 CCR4 (0.36) POLBALDH1A1GAANQO2
SCHEMBL30929289 0.72 CCR4 (0.36) POLBALDH1A1GAANQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615454-A1 SOS1 INHIBITORS Acerand Therapeutics (Hong Kong) Limited (HK) 2025-09-17 EP disclosed
US-20240190868-A1 SOS1 INHIBITORS ACERAND THERAPEUTICS (HONG KONG) LIMITED (HK) 2024-06-13 US disclosed
WO-2024102952-A1 SOS1 INHIBITORS ACERAND THERAPEUTICS (USA) LIMITED (US) 2024-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190868-A1 SOS1 INHIBITORS SOS1, SOS2, SOST POLB 3631/4885NNMT 4524/4885KDM4E 4441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.